Lebwohl M, Gooderham M, Warren RB, Thaçi D, Foley P, Gottlieb AB, Hippeli L, Kisa RM, Banerjee S, Griffiths CE. Deucravacitinib, an Oral, Selective, Allosteric Tyrosine Kinase 2 Inhibitor, in Moderate to Severe Plaque Psoriasis: Absolute PASI Outcomes Over 52 Weeks in the Phase 3 POETYK PSO-1 Trial. J of Skin [Internet]. 2023Nov.13 [cited 2024Jul.22];7(6):s239. Available from: https://jofskin.org/index.php/skin/article/view/2361